DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Via…
| Métrica | DBV.PA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -87.2% | -39.2% | -48.0% |
| ROA | -63.0% | -30.9% | -32.1% |
| Current Ratio | 3.67 | 2.73 | +0.94 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -63.0% | — |
| ✗Flujo de caja operativo positivo | −$120M | −$103M |
| ✓Rentabilidad sobre activos al alza | -63.0% | -174.1% |
| ✓Caja operativa/activos supera al ROA | -51.6% | ROA -63.0% |
| ✗Menos deuda a largo plazo | — | 0.0% |
| ✓Mejor liquidez (ratio corriente) | 3.67 | 1.43 |
| ✗Sin aumentar el nº de acciones | 140M | 97M |
| –Margen bruto al alza | — | — |
| ✗Rotación de activos al alza | — | 0.00 |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -83.8% |
DBV TECHNOLOGIES cotiza a 1.57 EUR y tiene una capitalización bursátil de €493M. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud